NCT05915663 Impact of the Choice of Gastric Tube Placement Sites on the Incidence of Ventilator Associated Pneumonia
| NCT ID | NCT05915663 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier le Mans |
| Condition | Intubated Patient Requiring a Gastric Tube |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,400 participants |
| Start Date | 2024-11-07 |
| Primary Completion | 2027-04-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,400 participants in total. It began in 2024-11-07 with a primary completion date of 2027-04-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In intensive care, many gastric tubes are inserted on a regular basis. There are different practices in terms of the location of the gastric tube. In some cases, the tube is inserted through the nose and in others, it is inserted through the mouth. In the literature and in practice, these gastric tubes create discomfort and complications that have an impact not only on the patient, but also on the treatments and the length of the patient's stay in hospital. Nosocomial Ventilator Associated Pneumonia is the most serious common complication for patients intubated with a gastric tube. It is possible that placement site may have an impact on the risk of developing Ventilator Associated Pneumonia, particularly by increasing the risk of bacterial pullulation opposite the sinuses when the tube is placed via the nasal route. Investigator hypothesises that placing the gastric tube orally will reduce the rate of ventilator-associated pneumonia compared with the nasal route in mechanically ventilated intensive care patients.
Eligibility Criteria
Inclusion Criteria: * patient in intensive care, intubated, ventilated * Adult * Requiring a gastric tube * With an expected duration of mechanical ventilation of more than 48 hours * Affiliated to social security * Patient or relative consent or, failing that, emergency inclusion of the patient Exclusion Criteria: * Pregnant, breast-feeding or parturient women * Patients under legal protection: curatorship and guardianship * Contraindication to placing a gastric tube through the nose or mouth * Patients who already have a gastric tube when they enter the service * Patient intubated for more than 24 hours * Patient intubated via the nasotracheal route
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05915663 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intubated Patient Requiring a Gastric Tube. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05915663 currently recruiting?
Yes, NCT05915663 is actively recruiting participants. Contact the research team at cjadeau@ch-lemans.fr for enrollment information.
Where is the NCT05915663 trial being conducted?
This trial is being conducted at Angers, France, Cholet, France, Grenoble, France, La Roche-sur-Yon, France and 11 additional locations.
Who is sponsoring the NCT05915663 clinical trial?
NCT05915663 is sponsored by Centre Hospitalier le Mans. The trial plans to enroll 2,400 participants.